

A Review on Current Scenario in Drug-Loaded Nanocapsules in Cancer Treatment

Randhir Patil¹, Manish Wani*¹, Dnyanesh Limaye¹, Poonam Patil¹, Ashwini Zade¹, Akshay Baheti¹, Mohamed Dehghan², Satish Polshettiwar¹, Amol Tagalpallewar¹

1. Department of Pharmaceutics, School of Pharmacy, Dr. Vishwanath Karad, MIT World Peace University, Pune 411038, Maharashtra, India.
2. Department of Pharmaceutics, Y.B Chavan College of Pharmacy, Dr Rafiq Zakaria Campus, Aurangabad 431001 Maharashtra, India

Email: manish.wani@mitwpu.edu.in

ABSTRACT

Various types of carriers presently available in care of cancer for targeted medicine delivery, each with its own combination of advantages and disadvantages. Polymeric nanocarrier like, micelles, dendrimers, magnetic and gold nanoparticles, liposomes, quantum dots, silica nanoparticles, polyethylene glycol, and carbon nanotubes were given special consideration. To achieve controlled drug release and effective delivery of drug, nanocapsule of dispersed polymer can be used as a drug transporter that is nanoscale in size. The main determinants, stability of dispersion are the surfactant structure and the outer coating shape. The structure and configuration of capsule walls have a major impact on release and deterioration characteristics of the capsules. The nanocapsule size range is between 1 to 100 nm. There are major methods for producing nanocapsules are polymerization, interfacial polymerization, arc discharge, emulsion polymerization and encapsulation of nanocapsule method. Measurement of capsule surface, Capsule radius distribution, thermal or chemical decomposition, capsule membrane thickness and permeability are the most significant capsule parameters.

Keywords: Nanocapsules; Cancer treatment; Drug-Loaded Nanocapsules; nanoencapsulation.

Introduction

Cancer is a word that refers to a group of diseases in which malignant cells develop abnormally and spread to other areas of the body^{1,2} which results to cause death, hence cancer is one of the deadly illnesses on the planet.

Nanomedicine is the recent nanotechnology in medicine which is composed of Nanomaterials, whose sizes vary from around one nanometer to many hundred nanometers^{3,4}.

Various considerations can affect the use of Cancer-fighting nanomaterials detection and medicine distribution in cancer treatment.

- The nanomaterial's size.
- The nanosystem's biocompatibility.
- The nanosystem's capacity to degrade.
- The drug's desired release profile.
- The encapsulated drug's toxicity and antigenicity.
- The entrapped medicine's properties in the nanomaterial
Ex. medications solubility or stability in water and other solvents.

Nanocapsules are a type of nanoparticle that consists of a protective matrix known as shell and one or more active materials known as core in which the therapeutic substance can be enclosed. The protective coating on the nano-capsules, this is usually pyrophoric and rapidly oxidizes⁵.

The use of nanoparticles as drug carriers has been widely studied, with majority of their applications in cancer care and detection. Chemotherapeutic agents that have been conjugated with or incorporated into nanocarriers are known as nanomedicines. Sustained release, increased medication selectivity as well as potency, enhanced drug bioavailability and reduced toxicity of drugs are the significant features. When nanocapsules injected through the IV route, which are submicron in size, hit the target and release the encapsulated compound.

Nanocapsules are polymeric nanoparticles with a polymeric wall which is made up of macromolecule, surfactants that are non-ionic oil base and phospholipids⁶⁻⁹. Interfacial nano-deposition and interfacial polymerization are the most popular methods for manufacturing of nanocapsules and they are used to deliver medicines in a controlled manner while also protecting proteins, enzymes and foreign cells.

Because of their adverse side effects, some medications have a difficult time finding a marketplace. When drugs are inserted within the space of a nanocapsule, however, nanocapsules deliver medication directly to the desired location in a reduced dose that is up to 10,000-fold and thereby significantly reduce or eliminate any side effects to a reasonable amount¹⁰.

Nanocapsule development can be influenced by their intended use as well as biochemical, electrical, pharmaceutical, magnetic and optical properties. The improved distribution of bioactive molecules through selective delivery by nanocapsules creates various obstacles and prospects for future study and development of better therapies.

Advantages of nanocapsule^{11,12}:

- At the molecular level, nanocapsules have the potential to penetrate and enter into specific tissue.
- Nanocapsules have huge surface area hence it provides high degree of absorption.
- Increased medication uptake and localization in cells.
- Drug distribution to cancerous cells is targeted and selective while avoiding conflicts with healthy cells.
- Because medications or small molecules are encapsulated, a lower dose is needed.
- Improved absorption of medications that are poorly soluble.
- Toxicity of medicines is reduced.
- Greater accuracy in drug delivery to the small body parts.
- Less drug resistance is produced.
- Resistance occurring from physiological barriers in the body is minimized or suppressed.

Limitations:

- The excessive use of detergent like poly vinyl alcohol can raise toxicity.
- Discontinuation of treatment is not possible.
- Inflammation of the alveoli and the lungs can occur.
- Nanoparticles interrupt autonomic function, which can affect cardiac and vascular function directly.

Materials, Composition and Method of Preparation

Materials:

In preparation of nanocapsules different types of polymers can be used-

1. Natural polymers: Ex. Gum Arabica
2. Synthetic polymers: Ex. Poly(L,D lactide), poly(E-caprolactone), poly(alkyl cyanoacrylate)
3. Semisynthetic polymers: Ex. Hydroxypropoxymethylcellulose Phthalate (HPMCP), Hydroxypropyl methylcellulose (HPMC), diacyl beta cyclodextrin^{13,14}.

Other than polymers, different oils including mineral oils or vegetable oils and pure compounds like benzyl benzoate and ethyl oleate also used for the preparation of nanocapsules.

Composition of nanocapsules

An aqueous or oily core is coated with a thin polymer membrane to form nanocapsules. These nanocapsules were made using an interfacial polymerization process for the monomer as well as a procedure for interfacial nanodeposition of prepared polymers. Tumor cells targeting nano-scale vectors capable of carrying radioactive particles are being developed and it has benefited greatly from technological advancements in the pharmaceutical research field¹⁵.

Methods

A. Polymerization method

To produce nanoparticles, the monomers are polymerized in an aqueous solution. Through dissolving the active ingredient in a polymerization medium or adsorbing nanoparticles, the drug is placed. The ultracentrifugation system used to sterilize the suspension of nanoparticles, eliminates the different surfactants and stabilizers used in

the polymerization process. The nanoparticles are then again suspended in a non-surfactant solution that is isotonic. It's been proposed that it could be used to make polybutylcyanoacrylate or polyalkylcyanoacrylate nanoparticles. Physical, chemical stabilizers and surfactant concentrations all serve a major role in the creation of nanocarriers and their particle size. The nanoparticles are formulated using a phase-inversion method and have a 20-100 nm of mean diameter which depends on the amount of additives used^{16,17}.

B. Interfacial polymerization method

Condensation polymers are bulk polymerized, which will require higher temperature is an alternative to interfacial polymerization. It is made up of two non-miscible solvents in which monomers in single solvent react immediately with monomers in another solvent and it is time dependent. The nanocapsules can be developed from an aqueous core containing isobutyl cyanoacrylate oligonucleotides in a water in oil emulsion then the nanocapsules are filtered using ultracentrifugation technique before being resuspended in aqueous solution to produce an aqueous core nanocapsule dispersion^{18,19,20}.

C. Arc-discharge method

Arc-discharge technology has been used to create accumulation of self-build nanocapsules. This system has also been changed into a modern way of synthesising aggregates using modified techniques, by adding GdAl₂ (gadolinium aluminium alloy) ingot which is anode. By modifying the amounts of materials in the anode based on their vaporisation pressures which helps to create a different kind of magnetic nanocapsule with the inner metallic element that is the core is GdAl₂, while the shell is amorphous Al₂O₃ (aluminium oxide) has been created, potentially expanding the group of magnetic nanocapsules. Without the use of a catalyst or template, an arc-discharge technique was used to build frequently arranged 3D macroaggregates self-build by nanocapsules²¹⁻²⁴.

D. Emulsion polymerization method

Two parts of the pre-emulsion is blended together. Part I consist of styrene (40 gm), divinylbenzene (0.8 gm), 2,2'-azobisisobutyronitrile (0.82 gm) and Desmodur BL3175A (40 gm) and Part II consist of sodium dodecyl sulphate (1.71 gm), Igepal CO-887 (1.63 gm) and water (220 gm). In different containers Parts I and part II are magnetically combined for ten minutes. The contents of Part II were then passed to Part I and mechanically stirred at 1,800 rpm for 30 minutes. Then pre-emulsion was chilled at 5°C before being sonicated (until a particle size of 250 nm was achieved) with a Misonix sonicator 3000. The pre-emulsion was degassed for 30 minutes in a 3 neck circular bottom flask which consist of mechanical stirrer, nitrogen inlet and reflux condenser²⁵. The temperature was raised to 70°C and kept for 8 hours to complete the polymerization. Chemical vapour deposition, electron irradiation deposition, charge transferring, laser vaporization-condensation, organic reagent aided process, catalytic vapor-liquid-solid growth and solution-liquid-solid method are some of the other nano-capsule preparation processes²⁶⁻³².

E. Encapsulation of nanocapsules method

Many encapsulation strategies use isocyanates in either a form of solvent or a bulk form to create shell or matrix substance for encapsulating usable materials and releasable fill materials^{33, 34}. Encapsulation postpones drug release from nanocapsules, such as Aerosil 200 and Xerogels are used as encapsulated products. The Aerosil 200 has the significant disadvantage of bursting nanocapsules. Several methods for reducing the outburst release of medicines from xerogel mesopores have also been suggested. It has been recommended that polymeric nanocapsules can be intended as a coating material for the accumulation of drug containing xerogel to prevent a severe burst release. They could delay the microparticles' interaction with water, preventing a burst and delaying drug release^{35, 36}.

Physical Characterization of Nanocapsule

Particle size:

The bioavailability, in-vivo distribution, targeting capability and toxicity of system of nanoparticles are all determined by particle shape and size and size distribution in nanocapsule systems. It also has an important impact on drug loading capability, release of drug and nanoparticulate system stabilisation. The impact of dose release and the lag period of pharmacological activity are based on size of particles. Since tiny particles have more surface area and many therapeutic drugs interact with surface particle which cause immediate release of drug, while big particles with large surface of core disperse out over time³⁷.

Surface area:

- (a) Surface coating of nanocapsules with hydrophilic surfactants and hydrophilic polymers³⁸,
- (b) Biodegradable copolymers having hydrophilic segments, such as polysorbate 80, polyoxamer, polyethylene oxide, poloxamine and polyethylene glycol, are prepared as nanocapsules. The charge present on a nanocapsule's surface described by using zeta potential³⁹.

Fluorescence intensity:

Fluorescence intensity is primarily used to confirm the location of nano-capsules containing an aqueous centre of oligonucleotides⁴⁰⁻⁴².

General Evaluation Methods of Nanocapsule

X-Ray Diffraction studies

Powder X-ray diffraction with graphite monochromatized using a Rigaku D/max-2000 diffractometer CuK α at current of 250 mA and a voltage of 50 kV is used to determine the phase of the materials. The phase composition of prepared products can be seen in the XRD pattern⁴³.

Scanning Electron Microscopy

The structure of clustered aggregates with branches made up of nanocapsules may be flocculent, with tiny clusters, large clusters, and huge branches appearing at various sizes, confirming the structures self-similar properties. It can be distinguished by using Philips XL-30 scanning electron microscope that displays the transparent morphology of small clusters at high magnification. Clusters are created by tiny particles adhering together to create a flocculent arrangement. A low-magnification SEM picture of coral-like structure having branched features along with the axial and directions in lengthwise can be shown^{44,45}.

Differential Scanning Calorimetry

Both open (without a lid) and closed (with a lid) samples are subjected to DSC examination (small hole in the pan capped centre). According to the observations, both approaches have similar thermal activity⁴⁶.

Transmission Electron Microscopy

Transmission electron microscopy can be used to investigate the transportation of nanocapsules, especially insulin-loaded nanocapsules, through the epithelium after they have been given orally to experimental rats and studied in-vivo and in-vitro. The ingestion of biodegradable nanocapsules in the intestine leads to insulin transfer through the epithelium mucosa, according to TEM findings^{47,48}.

High-Resolution Transmission Electron Microscopy

Core or shell configuration of the nanocapsules is distinctly seen in the complex morphology of the related nanocapsules studied using high-resolution transmission electron microscopy. Low-magnification TEM photographs are used to examine the composition of nanocapsules that make up the aggregates^{49,50}.

X-Ray Photoelectron Spectroscopy

The surface aluminium atoms valency existing on the nanocapsules at a range of 1.6 nm was determined by X-ray photoelectron spectroscopy quantification on an ESCALAB-250 with monochromatic x-ray sources. Due to the limited spectrum of photoelectrons excited, the XPS technique is particularly unique to the solid surface. A concentric hemispherical analyser (CHA) is used to calculate the photoelectrons excited energy which is emitted from the sample, which displays a spectrum of different photoelectron peaks. Depending on the element, the binding energies of the peaks change. The peak areas are used to demonstrate the structure of the surface materials (with similar susceptibility factors). The emitting atom of chemical state will alter the form of each peak and the binding energy moderately. Chemical bonding information is also provided by the XPS method⁵¹.

Superconducting Quantum Interference Device

Quantum Design MPMS-5s and MPMS-7s of SQUIDs are used to test the magnetic properties of nanocapsules. SQUID detectors are the most sensitive for detecting minute variations in magnetic flux, which accounts for the vast range of applications that SQUID instruments can be used⁵².

Multi Angle Laser Light Scattering

The shape of a vault is similar to a capsule shape with a very tiny shell (less than two nano meters) encasing a huge internal space. A nanocapsule's vault particle has enormous potential for compound encapsulation, safety, and distribution. Using multi angle laser light scattered to investigate vault conformation in solution, the interconversion of opened and closed conformers is stimulated. The regulation of entrapment and release of encapsulated materials is possible thanks to these tests. Vaults containing radioactive metal binding sites are crucial for environmental and medical detoxification⁵³⁻⁵⁶.

FT-IR analysis

FTIR analysis is used to establish the existence of distinctive peaks. The peaks represent the compound's characteristic functional units^{57,58}.

Use of Nanocapsules

Nanocapsules have the potential to be employed as smart medication that only bind to certain cells and have specific chemical receptors. This receptor is what gives the drug its "smart" properties, that allows it to target cancer cells.

The following are some of the benefits of nano-encapsulation technology applications for pharmaceuticals:

- Smaller dosage volumes with higher dosage loading.
- Increased dosage retention at certain sites.
- Increased absorption of active medication components.
- The drug's bioavailability has improved.
- Greater effectiveness and safety.
- Increased patient compliance⁵⁹.

Applications of Nanocapsules

1. Nanocapsules as novel Systems

The surfactant composition and the design of the outside layer are the key determinants of dispersion stability and primary physiological action. The composition and arrangement of the capsule walls have a big impact on their escape and degradation property. The significant capsule properties include surface of capsule, capsule radius distribution of capsule, membrane thickness of capsule and permeability of capsule and thermal and chemical decomposition.

2. Nanocapsules as Drug Delivery System

Australian scientists have created nanocapsules that can be intended for targeting anti-cancer agents on tumours while avoiding side effects on healthy tissue. The capsules, which are about 1 micron in diameter to a thousand of a millimetres can be covered with an antibody that are transferred from the bloodstream to the tumour. When it enters into the tumor, a rapid rupture without causing damage to the skin-penetrating lasers that produces near-infrared radiation, allows the capsules to break and release the contents.

3. Hormone-dependent breast cancer treatment

The research reveals that oestrogen receptor alpha (ER) can be targeted using complex siRNAs encapsulated in nanocapsules. After injecting these nanocapsules through IV into estradiol-stimulated MCF-7 cell xenografts, tumour formation and ER expression in tumour cells were significantly reduced. It implies that a new technique depend upon ER siRNA delivery for the treatment of hormone-dependent breast tumours might be developed⁶⁰.

4. The use of radioactive materials in nuclear nanocapsules for cancer treatment:

Astatine, like radium and uranium is radioactive compound, emits higher velocity alpha particles from radioactive decay of radioactive agents, that are approximately around 4,000 times quicker than the decay of beta released electrons, and it is frequently intended radioactive compound in treatment of the tumor. The alpha particle is special in that has a low penetration capacity and a large particle size, making it ideal for single-cell tumour targeting⁶¹.

5. Nanocapsules against melanomas

Melanoma's cancer are extremely aggressive tumours with a poor prognosis, particularly when it has spread. In contravention of major attempts in improving adjuvant treatments, that gives better response than the regular approved drug dacarbazine by the FDA which is less than 16%. The following steps should be taken to target specific cancer cell⁶²:

- i) Passive improved permeability retention because of the nanocapsules' size, structure and shape properties;
- ii) Antibody coupling allows for active targeting.

The physicochemical characteristics, half-life, aggregation at tumour site and therapeutic advantages of various nanocapsule forms have all been examined. The magnetic nanoparticles and selenium-based anti-cancer agent loaded poly(lactic-co-glycolic) nanocapsules provide an unique and strategically magnetic drug delivery mechanism suitable for the treatment of cancer via active drug and magneto hyperthermia⁶³.

Anticancer Drugs Formulated into Nanocapsule

Anticancer agents efficacy can be affected by high excretion, low water solubility and low permeability through the cells. The drug delivery technologies are intended to increase therapeutic agent's security and effectiveness while also increasing patient acceptance. Many medications containing the most commonly camptothecin, cisplatin, docetaxel, doxorubicin, paclitaxel and curcumin are being studied these days.

1. Paclitaxel

It's used to treat cancers of the ovary, lung, breast, neck, head and undisclosed origin. For more than two decades, this drug's less aqueous solubility has been a major barrier to its widespread use. Nanotechnologies is the type of polymer-based controlled release method have been proposed as one distribution strategy. OncoGel is a device that incorporates paclitaxel inside ReGel has been developed for local administration of paclitaxel to solid tumour cells for selective cytotoxicity. Several forms of cancer have been successfully treated using this delivery system. Paclitaxel can release from the ReGel at the tumour site and its surroundings area for six weeks⁶⁴⁻⁶⁷.

2. Docetaxel

Chemotherapeutic agents that are most commonly used in the solid tumour treatment. Its effectiveness has been shown against various tumours, including prostate and breast cancer. Zhang and co-workers made micelles that contains docetaxel to increase intracellular drug delivery and therapeutic effectiveness in cancerous cells. Both micelles had a less diameter (< 80 nm), a spherical in shape and a large encapsulation quality. The molecules containing DXT were evenly distributed inside micelles and did not interact chemically with the polymers.

3. Camptothecin

Camptothecin is a natural alkaloid, derived from the *Camptotheca acuminate* plant that inhibits DNA topoisomerase I action. It is difficult to administer to cancer cells due to its toxicity to human cells, unstable structure and non-polar properties. PEG-based nanoparticles, paramagnetic Fe₃O₄ nanoparticles and lipid nanoparticles have all been used in CPT-mediated drug delivery studies⁶⁸⁻⁷¹. Biodegradable, biocompatible and targeted sterically stabilised micelles are the nanocarriers used for camptothecin to overcome its insolubility, instability, and toxicity.

4. Doxorubicin

They are widely used in various types of malignant tumour treatment, involving acute leukaemia, Hodgkin's as well as non-Hodgkin's lymphoma and a variety of solid tumours like neuroblastoma⁷²⁻⁷⁵. The therapeutic use of this drug is limited by the side effects of combined dosage dependent cardiotoxicity, myelosuppression and the high delivery amount and short life span in physiological conditions^{76,77}. Using different nanoparticle forms as drug carriers such as micelles, polymer-based nanoparticles, magnetic particles and liposomes, these toxic effects have been effectively decreased⁷⁸⁻⁸⁰.

5. Daunorubicin

Daunorubicin is an anthracycline-based chemotherapeutic drug that is used to treat some cases of leukaemia (acute myeloid leukaemia and acute lymphocytic leukemia).

6. Cisplatin

Rosenberg identified the biological action of the very first platinum-based cytostatic compound that is cisplatin, which has now become one of the most commonly used cytotoxic agents, in 1965 while studying the influence of an electric current on bacterial development^{81,82}.

7. Curcumin

Curcumin is a natural polyphenol isolated from turmeric that has anti-carcinogenic properties and low inherent toxicity. Curcumin was shown to be pharmacologically stable in many human trials and animal studies, including at extremely high doses. It has a very low polarity and deteriorates rapidly in acidic as well as alkaline environments with a short half-life (<10) minutes, resulting in very less bioavailability following vascular and orally administration. Curcumin distribution through nanocarriers has recently been investigated as a way of avoiding these limitations⁸³.

Conclusion

To summarise, various nonencapsulated technologies include novel research pathways that are sufficient recent strategies for development in cancer diagnosis and diagnostic techniques, as well as drug administration in cancer therapy. In pharmaceutical industry, nonencapsulated structures in particular, play significant role in the administration of anticancer medicines. Nanoencapsulation has been used in medicine and greatly helped in the resolution of a number of issues including toxicity, drug absorption and improved solubility, tumour site targeting, drug resistance, and so on. Among the benefits are a reduction in the needed dose and regulated drug release. As a result, the nanomedicine use has transformed our capacity to detect tumour and treat it. Nanocapsules are a reference to the methodological advancement of multiple formulation processes, primarily interfacial polymerization and interfacial nano-deposition. Nanocapsules are also useful in a variety of areas, including agrochemicals, sewage treatment, gene therapy, makeup, hygiene materials, and adhesive materials. Eventually, they may be used to transport active pharmaceutical ingredients (APIs). In the future, they will have new and efficient drug delivery technologies.

Reference

1. Wiwanitkit, V. (2013). Cancer nanotherapy: Concept for design of new drug. *Journal of Medical Hypotheses and Ideas*, 7(1), 3-4.
2. Montané, X., Bajek, A., Roszkowski, K., Montornés, J. M., Giamberini, M., Roszkowski, S., ... & Tylkowski, B. (2020). Encapsulation for cancer therapy. *Molecules*, 25(7), 1605.
3. Oladimeji, O. D., & Adedoyin, A. Nanotechnology in Medical Practice.
4. Kawasaki, E. S., & Player, A. (2005). Nanotechnology, nanomedicine, and the development of new, effective therapies for cancer. *Nanomedicine: Nanotechnology, Biology and Medicine*, 1(2), 101-109.
5. Benita, S. (1998). Microparticulate drug delivery systems: release kinetic models. *Microspheres, Microcapsules & Liposomes*, 2, 155-181.

6. Jäger, A., Stefani, V., Guterres, S. S., & Pohlmann, A. R. (2007). Physico-chemical characterization of nanocapsule polymeric wall using fluorescent benzazole probes. *International journal of pharmaceutics*, 338(1-2), 297-305.
7. da Fonseca, L. S., Silveira, R. P., Deboni, A. M., Benvenutti, E. V., Costa, T. M., Guterres, S. S., & Pohlmann, A. R. (2008). Nanocapsule@ xerogelmicroparticles containing sodium diclofenac: a new strategy to control the release of drugs. *International journal of pharmaceutics*, 358(1-2), 292-295.
8. Béduneau, A., Saulnier, P., Anton, N., Hindré, F., Passirani, C., Rajerison, H., ... & Benoit, J. P. (2006). Pegylated nanocapsules produced by an organic solvent-free method: Evaluation of their stealth properties. *Pharmaceutical research*, 23(9), 2190-2199.
9. Mohanraj, V. J., & Chen, Y. (2006). Nanoparticles-a review. *Tropical journal of pharmaceutical research*, 5(1), 561-573.
10. Radhika, P. R., & Sivakumar, T. (2011). Nanocapsules: a new approach in drug delivery. *International Journal of Pharmaceutical Sciences and Research*, 2(6), 1426.
11. Farokhzad, O. C., & Langer, R. (2009). Impact of nanotechnology on drug delivery. *ACS nano*, 3(1), 16-20.
12. Chow, E. K. H., & Ho, D. (2013). Cancer nanomedicine: from drug delivery to imaging. *Science translational medicine*, 5(216), 216rv4-216rv4.
13. Novak, B. M. (1993). Hybrid nanocomposite materials—between inorganic glasses and organic polymers. *Advanced Materials*, 5(6), 422-433.
14. Wan, L. S., Heng, P. W., & Chia, C. G. (1992). Spray drying as a process for microencapsulation and the effect of different coating polymers. *Drug development and industrial pharmacy*, 18(9), 997-1011.
15. Kim, D., Kim, E., Lee, J., Hong, S., Sung, W., Lim, N., ... & Kim, K. (2010). Direct synthesis of polymer nanocapsules: self-assembly of polymer hollow spheres through irreversible covalent bond formation. *Journal of the American Chemical Society*, 132(28), 9908-9919.
16. Zhang, Q., Shen, Z., & Nagai, T. (2001). Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. *International journal of pharmaceutics*, 218(1-2), 75-80.
17. Boudad, H., Legrand, P., Lebas, G., Cheron, M., Duchene, D., & Ponchel, G. (2001). Combined hydroxypropyl- β -cyclodextrin and poly (alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. *International journal of pharmaceutics*, 218(1-2), 113-124.
18. Lambert, G., Fattal, E., Pinto-Alphandary, H., Gulik, A., & Couvreur, P. (2000). Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. *Pharmaceutical research*, 17(6), 707-714.
19. Kothamasu, P., Kanumur, H., Ravur, N., Maddu, C., Parasuramrajam, R., & Thangavel, S. (2012). Nanocapsules: the weapons for novel drug delivery systems. *BioImpacts: BI*, 2(2), 71.
20. Jang, J., Bae, J., & Park, E. (2006). Selective Fabrication of Poly (3, 4-ethylenedioxythiophene) Nanocapsules and Mesocellular Foams Using Surfactant-Mediated Interfacial Polymerization. *Advanced Materials*, 18(3), 354-358.
21. Ma, S., Geng, D., Zhang, W., Liu, W., Ma, X., & Zhang, Z. (2006). Synthesis of a new type of GdAl₂ nanocapsule with a large cryogenic magnetocaloric effect and novel coral-like aggregates self-assembled by nanocapsules. *Nanotechnology*, 17(21), 5406.
22. Yosida, Y., Shida, S., Ohsuna, T., & Shiraga, N. (1994). Synthesis, identification, and growth mechanism of Fe, Ni, and Co crystals encapsulated in multiwalled carbon nanocages. *Journal of applied physics*, 76(8), 4533-4539.
23. Zhong, Z., Chen, H., Tang, S., Ding, J., Lin, J., & Tan, K. L. (2000). Catalytic growth of carbon nanoballs with and without cobalt encapsulation. *Chemical Physics Letters*, 330(1-2), 41-47.
24. Zhang, Z. D. (2004). Nanocapsules. In *Encyclopedia of nanoscience and nanotechnology* (Vol. 6, No. 160, pp. 77-160). American Scientific Publishers.
25. Jackson, L. S., & Lee, K. (1991). Microencapsulation and the food industry. *Lebensm. Wiss. Technol*, 24(4), 289-297.
26. Dick, K. A., Deppert, K., Larsson, M. W., Mårtensson, T., Seifert, W., Wallenberg, L. R., & Samuelson, L. (2004). Synthesis of branched 'nanotrees' by controlled seeding of multiple branching events. *Nature materials*, 3(6), 380-384.
27. Lee, E. J., Lee, H. M., Li, Y., Hong, L. Y., Kim, D. P., & Cho, S. O. (2007). Hierarchical pore structures fabricated by electron irradiation of silicone grease and their applications to superhydrophobic and superhydrophilic films. *Macromolecular rapid communications*, 28(3), 246-251.

28. El-Shall, M. S., Li, S., Graiver, D., & Pernisz, U. (1996). Synthesis of Nanostructured Materials Using a Laser Vaporization—Condensation Technique.
29. Naka, K., Itoh, H., & Chujo, Y. (2003). Temperature-dependent reversible self-assembly of gold nanoparticles into spherical aggregates by molecular recognition between pyrenyl and dinitrophenyl units. *Langmuir*, *19*(13), 5496-5501.
30. Lu, Q., Gao, F., & Zhao, D. (2002). The assembly of semiconductor sulfidenanocrystallites with organic reagents as templates. *Nanotechnology*, *13*(6), 741.
31. Zhu, Y. Q., Hsu, W. K., Zhou, W. Z., Terrones, M., Kroto, H. W., & Walton, D. R. M. (2001). Selective Co-catalysed growth of novel MgO fishbone fractal nanostructures. *Chemical physics letters*, *347*(4-6), 337-343.
32. Boal, A. K., Ilhan, F., DeRouchey, J. E., Thurn-Albrecht, T., Russell, T. P., & Rotello, V. M. (2000). Self-assembly of nanoparticles into structured spherical and network aggregates. *Nature*, *404*(6779), 746-748.
33. Matkan, J., & Treleaven, R. J. (1987). *U.S. Patent No. 4,681,806*. Washington, DC: U.S. Patent and Trademark Office.
34. Yang, H., Mendon, S. K., & Rawlins, J. W. (2008). Nanoencapsulation of blocked isocyanates through aqueous emulsion polymerization. *eXPRESS Polymer Letters*, *2*(5), 349-356.
35. Arenas, L. T., Dias, S. L., Moro, C. C., Costa, T. M., Benvenuti, E. V., Lucho, A. M., & Gushikem, Y. (2006). Structure and property studies of hybrid xerogels containing bridged positively charged 1, 4-diazoniabicyclo [2.2. 2] octane dichloride. *Journal of colloid and interface science*, *297*(1), 244-250.
36. Slowing, I. I., Trewyn, B. G., Giri, S., & Lin, V. Y. (2007). Mesoporous silica nanoparticles for drug delivery and biosensing applications. *Advanced Functional Materials*, *17*(8), 1225-1236.
37. Redhead, H. M., Davis, S. S., & Illum, L. (2001). Drug delivery in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. *Journal of Controlled Release*, *70*(3), 353-363.
38. Jang, J., Bae, J., & Park, E. (2006). Selective Fabrication of Poly (3, 4-ethylenedioxythiophene) Nanocapsules and Mesocellular Foams Using Surfactant-Mediated Interfacial Polymerization. *Advanced Materials*, *18*(3), 354-358.
39. Couvreur, P., Barratt, G., Fattal, E., & Vauthier, C. (2002). Nanocapsule technology: a review. *Critical Reviews™ in Therapeutic Drug Carrier Systems*, *19*(2).
40. Lambert, G., Fattal, E., Pinto-Alphandary, H., Gulik, A., & Couvreur, P. (2000). Polyisobutylcyanoacrylatenanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. *Pharmaceutical research*, *17*(6), 707-714.
41. Smith, P. B., Dendramis, K. A., & Chiu, D. T. (2010). Investigating lyophilization of lipid nanocapsules with fluorescence correlation spectroscopy. *Langmuir*, *26*(12), 10218-10222.
42. Sun, B., & Chiu, D. T. (2003). Spatially and temporally resolved delivery of stimuli to single cells. *Journal of the American Chemical Society*, *125*(13), 3702-3703.
43. Aiyer, N. H., Seshadri, R., Raina, G., Sen, R., & Rao, N. R. C. (1995). Study of Carbon Nanocapsules (Onions) and Spherulitic Graphite by Stm and Other Techniques.
44. Watanasirichaikul, S., Davies, N. M., Rades, T., & Tucker, I. G. (2000). Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions. *Pharmaceutical research*, *17*(6), 684-689.
45. Lee, E. J., Lee, H. M., Li, Y., Hong, L. Y., Kim, D. P., & Cho, S. O. (2007). Hierarchical pore structures fabricated by electron irradiation of silicone grease and their applications to superhydrophobic and superhydrophilic films. *Macromolecular rapid communications*, *28*(3), 246-251.
46. Wicks, D. A., & Wicks Jr, Z. W. (1999). Blocked isocyanates III: Part A. Mechanisms and chemistry. *Progress in Organic Coatings*, *36*(3), 148-172.
47. Kępczyński, M., Bednar, J., Lewandowska, J., Staszewska, M., & Nowakowska, M. (2009). Hybrid silica-silicone nanocapsules obtained in cationic vesicles. Cryo-TEM studies. *Journal of nanoscience and nanotechnology*, *9*(5), 3138-3143.
48. Pinto-Alphandary, H., Aboubakar, M., Jaillard, D., Couvreur, P., & Vauthier, C. (2003). Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. *Pharmaceutical research*, *20*(7), 1071-1084.
49. Ma, S., Geng, D., Zhang, W., Liu, W., Ma, X., & Zhang, Z. (2006). Synthesis of a new type of GdAl₂ nanocapsule with a large cryogenic magnetocaloric effect and novel coral-like aggregates self-assembled by nanocapsules. *Nanotechnology*, *17*(21), 5406.

50. Zhang, Z. D., Zheng, J. G., Skorvanek, I., Wen, G. H., Kovac, J., Wang, F. W., ... & Zhang, X. X. (2001). Shell/core structure and magnetic properties of carbon-coated Fe-Co (C) nanocapsules. *Journal of Physics: Condensed Matter*, 13(9), 1921.
51. Beck, R. C. R., Lionzo, M. I. Z., Costa, T. M. H., Benvenuti, E. V., Ré, M. I., Gallas, M. R., ... & Guterres, S. S. (2008). Surface morphology of spray-dried nanoparticle-coated microparticles designed as an oral drug delivery system. *Brazilian Journal of chemical engineering*, 25(2), 389-398.
52. Liu, X. G., Li, B., Geng, D. Y., Cui, W. B., Yang, F., Xie, Z. G., ... & Zhang, Z. D. (2009). (Fe, Ni)/C nanocapsules for electromagnetic-wave-absorber in the whole Ku-band. *Carbon*, 47(2), 470-474.
53. Kedersha, N. L., Heuser, J. E., Chugani, D. C., & Rome, L. H. (1991). Vaults. III. Vault ribonucleoprotein particles open into flower-like structures with octagonal symmetry. *Journal of Cell Biology*, 112(2), 225-235.
54. Kothamasu, P., Kanumur, H., Ravur, N., Maddu, C., Parasuramrajam, R., & Thangavel, S. (2012). Nanocapsules: the weapons for novel drug delivery systems. *BioImpacts: BI*, 2(2), 71.
55. Stephen, A. G., Raval-Fernandes, S., Huynh, T., Torres, M., Kickhoefer, V. A., & Rome, L. H. (2001). Assembly of vault-like particles in insect cells expressing only the major vault protein. *Journal of Biological Chemistry*, 276(26), 23217-23220.
56. Park, S., Cho, H. Y., Yoon, J. A., Kwak, Y., Srinivasan, A., Hollinger, J. O., ... & Matyjaszewski, K. (2010). Photo-cross-linkable thermoresponsive star polymers designed for control of cell-surface interactions. *Biomacromolecules*, 11(10), 2647-2652.
57. Bouchemal, K. S. E. H. I. N., Briançon, S., Perrier, E., Fessi, H., Bonnet, I., & Zydowicz, N. (2004). Synthesis and characterization of polyurethane and poly (ether urethane) nanocapsules using a new technique of interfacial polycondensation combined to spontaneous emulsification. *International Journal of Pharmaceutics*, 269(1), 89-100.
58. Pavan, F. A., Gobbi, S. A., Costa, T. M. H., & Benvenuti, E. V. (2002). FTIR thermal analysis on anilinepropylsilicaxerogel. *Journal of thermal analysis and calorimetry*, 68(1), 199-206.
59. Mayer, C. (2005). Nanocapsules as drug delivery systems. *The International journal of artificial organs*, 28(11), 1163-1171.
60. Kothamasu, P., Kanumur, H., Ravur, N., Maddu, C., Parasuramrajam, R., & Thangavel, S. (2012). Nanocapsules: the weapons for novel drug delivery systems. *BioImpacts: BI*, 2(2), 71.
61. Deutsch, E., Libson, K., Vanderheyden, J. L., Ketring, A. R., & Maxon, H. R. (1986). The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. *International Journal of radiation applications and instrumentation. Part B. Nuclear Medicine and Biology*, 13(4), 465-477.
62. Curie, M. (2011). Novel lipid nanocapsules of anti alpha 1 sodium pump subunit SiRNA to specifically target metastatic melanomas. *European commission euraxess*, 11, 37.
63. Falqueiro, A. M., Primo, F. L., Morais, P. C., Mosiniewicz-Szablewska, E., Suchocki, P., & Tedesco, A. C. (2011). Selol-loaded magnetic nanocapsules: A new approach for hyperthermia cancer therapy. *Journal of Applied Physics*, 109(7), 07B306.
64. Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Arbuck, S. G., & Donehower, R. C. (1993, August). Clinical toxicities encountered with paclitaxel (Taxol). In *Seminars in oncology* (Vol. 20, No. 4 Suppl 3, pp. 1-15).
65. Marupudi, N. I., Han, J. E., Li, K. W., Renard, V. M., Tyler, B. M., & Brem, H. (2007). Paclitaxel: a review of adverse toxicities and novel delivery strategies. *Expert opinion on drug safety*, 6(5), 609-621.
66. Fiorica, F., Di Bona, D., Schepis, F., Licata, A., Shahied, L., Venturi, A., ... & Camma, C. (2004). Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. *Gut*, 53(7), 925-930.
67. Elstad, N. L., & Fowers, K. D. (2009). OncoGel (ReGel/paclitaxel)—Clinical applications for a novel paclitaxel delivery system. *Advanced drug delivery reviews*, 61(10), 785-794.
68. Shen, Y., Tang, H., Zhan, Y., Van Kirk, E. A., & Murdoch, W. J. (2009). Degradable poly (β -amino ester) nanoparticles for cancer cytoplasmic drug delivery. *Nanomedicine: nanotechnology, biology and medicine*, 5(2), 192-201.
69. Ueki, K., Onishi, H., Sasatsu, M., & Machida, Y. (2009). Preparation of carboxy-PEG-PLA nanoparticles loaded with camptothecin and their body distribution in solid tumor-bearing mice. *Drug Development Research*, 70(7), 512-519.

70. Zhu, A., Luo, X., & Dai, S. (2009). Chitosan-poly (acrylic acid) complex modified paramagnetic Fe₃O₄ nanoparticles for camptothecin loading and release. *Journal of Materials Research*, 24(7), 2307-2315.
71. HUANG, Z. R., HUA, S. C., YANG, Y. L., & FANG, J. Y. (2008). Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. *ActaPharmacologicaSinica*, 29(9), 1094-1102.
72. Zhu, S., Hong, M., Tang, G., Qian, L., Lin, J., Jiang, Y., & Pei, Y. (2010). Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. *Biomaterials*, 31(6), 1360-1371.
73. Bisht, S., & Maitra, A. (2009). Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, 1(4), 415-425.
74. Kang, K. W., Chun, M. K., Kim, O., Subedi, R. K., Ahn, S. G., Yoon, J. H., & Choi, H. K. (2010). Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. *Nanomedicine: Nanotechnology, Biology and Medicine*, 6(2), 210-213.
75. Khdaier, A., Chen, D., Patil, Y., Ma, L., Dou, Q. P., Shekhar, M. P., & Panyam, J. (2010). Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. *Journal of Controlled Release*, 141(2), 137-144.
76. Manocha, B., & Margaritis, A. (2010). Controlled release of doxorubicin from doxorubicin/-polyglutamic acid ionic complex. *Journal of Nanomaterials*, 2010.
77. Asadishad, B., Vossoughi, M., & Alamzadeh, I. (2010). In vitro release behavior and cytotoxicity of doxorubicin-loaded gold nanoparticles in cancerous cells. *Biotechnology letters*, 32(5), 649-654.
78. Yang, X., Chen, L., Han, B., Yang, X., & Duan, H. (2010). Preparation of magnetite and tumor dual-targeting hollow polymer microspheres with pH-sensitivity for anticancer drug-carriers. *Polymer*, 51(12), 2533-2539.
79. Grange, C., Geninatti-Crich, S., Esposito, G., Alberti, D., Tei, L., Bussolati, B., ... & Camussi, G. (2010). Combined Delivery and Magnetic Resonance Imaging of Neural Cell Adhesion Molecule-Targeted Doxorubicin-Containing Liposomes in Experimentally Induced Kaposi's Sarcoma. *Cancer research*, 70(6), 2180-2190.
80. Choubey, J., & Bajpai, A. K. (2010). Investigation on magnetically controlled delivery of doxorubicin from superparamagnetic nanocarriers of gelatin crosslinked with genipin. *Journal of Materials Science: Materials in Medicine*, 21(5), 1573-1586.
81. Petrlova, J., Potesil, D., Zehnalek, J., Sures, B., Adam, V., Trnkova, L., & Kizek, R. (2006). Cisplatin electrochemical biosensor. *Electrochimica Acta*, 51(24), 5169-5173.
82. Rosenberg, B., Van Camp, L., & Krigas, T. (1965). Inhibition of cell division in *Escherichia coli* by electrolysis products from a platinum electrode. *Nature*, 205(4972), 698-699.
83. Tang, H., Murphy, C. J., Zhang, B., Shen, Y., Van Kirk, E. A., Murdoch, W. J., & Radosz, M. (2010). Curcumin polymers as anticancer conjugates. *Biomaterials*, 31(27), 7139-7149.